US Multiple Sclerosis (MS) Registry
Corrona launched a Multiple Sclerosis(MS) Registry in August 2017.
The primary objective of the registry is to prospectively study the natural history of MS, the prevalence and incidence of comorbidities, and targeted adverse events, as well as the utilization patterns and the comparative effectiveness and comparative safety of approved MS treatments.
The Corrona MS Registry is enrolling patients diagnosed with Multiple Sclerosis. Data is collected from both patients and their treating neurologists at regular outpatient office visits.
In general, clinical trials provide safety data on new treatments for 6 to 12 months, but the long-term safety profiles of agents remain unclear. As new drugs are approved for multiple sclerosis patients, there is a growing need for an independent registry that will collect long-term real world data on safety, comorbidities, and quality of life.
- Led by our Scientific Advisory Group headed by Dr. Daniel Kantor, Kantor Neurology.
- Prospective, multicenter, observational disease-based registry.
- SAEs and AEs of special interest collected (MACE, malignancies, infection, etc).
- Data collection from both treating neurologist and patient at routine outpatient visits.
- ~50 U.S. neurology sites planned; enrollment of 3-5,000 MS patients.
- Payment for baseline, follow-up visits and adverse event reporting.